Literature DB >> 18245528

T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome.

Frederic Baleydier1, Anne-Valerie Decouvelaere, Julie Bergeron, Philippe Gaulard, Danielle Canioni, Yves Bertrand, Stephane Lepretre, Barbara Petit, Herve Dombret, Kheira Beldjord, Thierry Molina, Vahid Asnafi, Elizabeth Macintyre.   

Abstract

PURPOSE: T lymphoblastic lymphomas (T-LBL) are rare disorders of immature T cells which predominantly involve the mediastinum. Their oncogenic pathways and prognostic variables are not clear. EXPERIMENTAL
DESIGN: We undertook a retrospective study of 41 cytoplasmic CD3+ T-LBL (nine cases aged <16 years) by assessing stage of maturation arrest based on T cell receptor (TCR) immunogenotyping, immunohistochemistry, and quantification of the oncogenes thought to be important in immature T cell malignancies.
RESULTS: Application of a TCR-based immunogenetic classification allowed the identification of three subcategories: 11 immature IM0/D-LBL showed no TCR or only incomplete TCRD DJ rearrangement and corresponded to cytoplasmic CD3+ precursors of uncertain lineage. Sixteen mature TCRD(del)-LBL showed biallelic TCRD deletion and both TCRG and TCRB rearrangement, consistent with TCRalphabeta lineage restriction. Fourteen intermediate LBL (Int-LBL) showed complete TCRD VDJ and TCRG VJ rearrangement, with TCRB VDJ rearrangement in the majority. All Int-LBL expressed HOX11/TLX1 or HOXA9 transcripts and a proportion of the latter were associated with CALM-AF10 or NUP214-ABL fusion transcripts. IM0/D-LBL were restricted to adults with extrathymic disease and bone marrow involvement, whereas Int-LBL and TCRD(del)-LBL were found in children and adults with predominantly thymic disease. In adults, the Int-LBL subgroup was associated with a significantly superior clinical outcome. This subgroup can be identified either by TCR immunogenotyping or HOXA9/TLX1 transcript quantification.
CONCLUSION: Application of this molecular classification will allow the prospective evaluation of prognostic effects within pediatric and adult protocols.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245528     DOI: 10.1158/1078-0432.CCR-07-1927

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

Review 1.  T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?

Authors:  Emma Kroeze; Jan L C Loeffen; Vera M Poort; Jules P P Meijerink
Journal:  Blood Adv       Date:  2020-07-28

Review 2.  Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.

Authors:  Rodney R Miles; Rikin K Shah; J Kimble Frazer
Journal:  Br J Haematol       Date:  2016-03-11       Impact factor: 6.998

3.  Phosphorylation of HOX11/TLX1 on Threonine-247 during mitosis modulates expression of cyclin B1.

Authors:  Edwin Chen; Xiaoyong Huang; Yanzhen Zheng; You-Jun Li; Alden Chesney; Yaacov Ben-David; Eric Yang; Margaret R Hough
Journal:  Mol Cancer       Date:  2010-09-16       Impact factor: 27.401

4.  HOX proteins and leukemia.

Authors:  Kajal V Sitwala; Monisha N Dandekar; Jay L Hess
Journal:  Int J Clin Exp Pathol       Date:  2008-03-30

5.  T-cell lymphoblastic lymphoma presenting with pleural effusion: A case report.

Authors:  Xin-Liang He; Fan Yu; Tao Guo; Fei Xiang; Xiao-Nan Tao; Jian-Chu Zhang; Qiong Zhou
Journal:  Respir Med Case Rep       Date:  2014-05-04

6.  Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma.

Authors:  Elena Pomari; Federica Lovisa; Elisa Carraro; Simona Primerano; Emanuele S G D'Amore; Paolo Bonvini; Luca Lo Nigro; Rita De Vito; Luciana Vinti; Piero Farruggia; Marta Pillon; Giuseppe Basso; Katia Basso; Lara Mussolin
Journal:  Oncotarget       Date:  2017-11-11

7.  Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance.

Authors:  Tasneem Khanam; Sarah Sandmann; Jochen Seggewiss; Charlotte Ruether; Martin Zimmermann; Allison B Norvil; Christoph Bartenhagen; Gerrit Randau; Stephanie Mueller; Heidi Herbrueggen; Per Hoffmann; Stefan Herms; Lanying Wei; Marius Woeste; Christian Wuensch; Humaira Gowher; Ilske Oschlies; Wolfram Klapper; Wilhelm Woessmann; Martin Dugas; Birgit Burkhardt
Journal:  Blood       Date:  2021-04-29       Impact factor: 22.113

8.  T Cell-Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation for Treatment of T-Lymphoblastic Lymphoma.

Authors:  Lixun Guan; Xiaohong Li; Huaping Wei; Zhenyang Gu; Shasha Zhao; Chengying Zhu; Nan Yang; Feiyan Wang; Lan Luo; Zhe Gao; Wenrong Huang; Honghua Li; Quanshun Wang; Daihong Liu; Xiaoxiong Wu; Chunji Gao
Journal:  Ann Transplant       Date:  2018-06-22       Impact factor: 1.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.